Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

PHASE3RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

May 31, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

Gleolan

Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.

Trial Locations (6)

10128

RECRUITING

Mount Sinai, New York

17403

RECRUITING

WellSpan Health, York

21201

RECRUITING

University of Maryland, Baltimore

21401

TERMINATED

Luminis Health Anne Arundel Medical Center, Annapolis

55905

RECRUITING

Mayo Clinic Methodist Campus, Rochester

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

Sponsors
All Listed Sponsors
lead

NX Development Corp

INDUSTRY